ssussu
☆    

China,
2017-08-29 13:38
(3220 d 11:37 ago)

Posting: # 17748
Views: 3,346
 

 Extended release dosage form BE design [Design Issues]

Post reply
Dear all,
According to the FDA guidance for Mirabegron extended release tablets, there are 3 studies included. Why the study of 25mg strenth under fed condition dose not need?
Additionally, about a extended release drug，if the half life is very long e.g. 70hr，dose the AUC truncte to AUC0-72h?
Is there guidance for extended release drug specially from FDA?

Please kindly give me some advice. Thank you!
 
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
161 visitors (0 registered, 161 guests [including 30 identified bots]).
Forum time: 01:16 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5